Population Pharmacokinetic and Exposure‐Response Analysis of Vancomycin Nephrotoxicity in Cystic Fibrosis Patients
Pediatric Pulmonology · 2026-08 · 61 (8)
DOI: 10.1002/ppul.71748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 27.07.2026. Verfasst von Jessica Barry und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Vancomycin, Cystic Fibrosis, Anti-Bacterial Agents, Staphylococcal Infections. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Cystic Fibrosis Foundation, National Institutes of Health's National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Introduction
Acute pulmonary exacerbations (APE) in persons with cystic fibrosis (PwCF) are associated with a reduction in long‐term pulmonary function. Vancomycin is recommended as first‐line treatment of methicillin‐resistant Staphylococcus aureus ‐APE in PwCF. While vancomycin poses a significant risk of nephrotoxicity, the relationship between vancomycin exposure and nephrotoxicity in PwCF has not been characterized.
Aims
We aimed to establish the relationship between vancomycin exposure and onset of nephrotoxicity in PwCF, and to identify predictors of nephrotoxicity.
Methods
This was a retrospective study among 52 adults PwCF. Nephrotoxicity events were defined based on the RIFLE criteria, as a serum creatinine increase of 1.5 times from baseline or a ≥ 25% decrease in glomerular filtration rate. A population pharmacokinetic (popPK) model was used to derive exposure measures (i.e., area‐under the concentration‐time curve (AUC)).
Results
A total of 590 vancomycin serum concentrations were available for analysis. A one‐compartment model best describes vancomycin pharmacokinetics. Creatinine clearance was included as a significant covariate in the clearance. The popPK model allowed quantification of cumulative AUC (AUC cum ) and AUC 24 values, and AUC normalized (AUC norm ) and cumulative dose were further calculated. Each variable of interest was used to fit a generalized linear mixed‐effects (GLM) model. The GLM model identified AUC cum as a significant predictor of vancomycin nephrotoxicity ( p < 0.01). Additionally, patients with more than one dosing occasion were significantly more likely to experience nephrotoxicity ( p < 0.01). Based on the final AUC cum model, the odds of experiencing a nephrotoxicity event increased by 32.6% (95% CI: 11.0%–58.4%) for each doubling of AUC cum .
Discussion
Our results demonstrate an association between increased vancomycin exposures and risk of nephrotoxicity. This study provides a foundation for optimizing personalized vancomycin dosing strategies in PwCF to balance efficacy and nephrotoxicity risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
- Leiden University, Leiden, the Netherlands.
- Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, USA.
- The Minnesota Cystic Fibrosis Center, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: Jessica Barry, J G C van Hasselt, Michael Evans, Elizabeth B Hirsch, Sílvia M Illamola
Förderung
- NCATS NIH HHS
- Cystic Fibrosis Foundation
- National Institutes of Health's National Center for Advancing Translational Sciences
Zitieren
APA
Barry, J., van Hasselt, J. G. C., Evans, M., Hirsch, E. B., Dunitz, J., Shockley, S., Billings, J., & Illamola, S. M. (2026). Population Pharmacokinetic and Exposure‐Response Analysis of Vancomycin Nephrotoxicity in Cystic Fibrosis Patients. Pediatric Pulmonology, 61(8). https://doi.org/10.1002/ppul.71748
Vancouver
Barry J, van Hasselt JGC, Evans M, Hirsch EB, Dunitz J, Shockley S, et al. Population Pharmacokinetic and Exposure‐Response Analysis of Vancomycin Nephrotoxicity in Cystic Fibrosis Patients. Pediatric Pulmonology. 2026;61(8). doi:10.1002/ppul.71748
BibTeX
@article{Barry2026,
author = {Barry, Jessica and van Hasselt, J G C and Evans, Michael and Hirsch, Elizabeth B and Dunitz, Jordan and Shockley, Sarah and Billings, Joanne and Illamola, Sílvia M},
title = {Population Pharmacokinetic and Exposure‐Response Analysis of Vancomycin Nephrotoxicity in Cystic Fibrosis Patients},
journal = {Pediatric Pulmonology},
year = {2026},
volume = {61},
number = {8},
doi = {10.1002/ppul.71748}
}
EUVIMED